Question explored with the scientific record
Is there a long-term covid is there a long-term covid
Long COVID is real, well-documented, and carries measurable risks that persist for years.
The evidence is clear that a significant fraction of people who had COVID-19 develop ongoing symptoms. A 2025 review estimates global prevalence at about 36% of survivors, with fatigue, shortness of breath, and cognitive problems ("brain fog") among the most common complaints [5]. A large US insurance study found that people with post-COVID condition had roughly double the risk of heart failure, stroke, and pulmonary embolism over the next year compared to matched controls who never had COVID [3]. The risk of dying from any cause was also higher: about 2.8% versus 1.2% in the year after diagnosis [3].
The mechanisms are increasingly understood. The virus can persist in tissues long after the acute infection clears [5]. This drives ongoing inflammation, immune dysregulation, and damage to small blood vessels and nerves [5]. A 2022 study found that over half of long COVID patients with autonomic symptoms had abnormal nerve fiber density on skin biopsy, indistinguishable from patients diagnosed with postural orthostatic tachycardia syndrome (POTS) [1]. A case report describes a previously healthy 27-year-old runner who developed severe POTS five weeks after a mild COVID infection [2].
The evidence also shows that vaccination before infection reduces the risk of developing long COVID by roughly half [5]. But the condition can still occur after breakthrough infections, and the risk appears to accumulate with each reinfection, especially in vulnerable groups like those with pre-existing lung disease [4].
| Outcome | Post-COVID group | No-COVID controls | Risk ratio |
|---|---|---|---|
| COPD exacerbation | 32% | 16.5% | 1.94 |
| Pulmonary embolism/DVT | 8.0% | 2.2% | 6.23 |
| Cardiac arrhythmia | 29.5% | 12.5% | 2.97 |
| Heart failure | 11.8% | 6.0% | 2.53 |
| All-cause mortality | 2.8% | 1.2% | ~2.3 |
My call: Long COVID is a real, biologically grounded syndrome with documented organ damage and increased mortality. The evidence is strong enough to take the condition seriously and to avoid infection when possible. Confidence: high.
Sources used 5
-
Autonomic Nerve Involvement in Post-Acute Sequelae of SARS-CoV-2 Syndrome (PASC)
In a retrospective comparison, PASC patients referred for autonomic symptoms frequently had abnormal autonomic function tests and their clinical and autonomic features were indistinguishable from POTS patients.
DOI: 10.3390/jcm12010073 -
Severe Post-COVID-19 dysautonomia: a case report
A previously healthy 27-year-old female runner developed severe postural orthostatic tachycardia syndrome (POTS) and debilitating dysautonomia approximately five weeks after a mild COVID-19 infection, with symptoms including post-exertional fatigue, cognitive slowing, palpitatio…
DOI: 10.1186/s12879-022-07181-0 -
One-Year Adverse Outcomes Among US Adults With Post–COVID-19 Condition vs Those Without COVID-19 in a Large Commercial Insurance Database
Post-COVID-19 condition (PCC) markedly increases 12-month risks of cardiovascular and pulmonary events and mortality compared with matched non-COVID controls in a large US commercial-insurance population.
DOI: 10.1001/jamahealthforum.2023.0010 -
SARS-CoV-2 reinfection in interstitial lung disease patients and its association with clinical deterioration: a two-year prospective cohort study
In a two-year prospective cohort of ILD patients with prior COVID-19, repeated SARS-CoV-2 infections were linked to greater disease deterioration and faster FVC decline, with reinfection frequency, baseline fibrosis, respiratory failure, and COVID-19 pneumonia identified as inde…
DOI: 10.1186/s12879-025-12020-z -
Long COVID: mechanisms of disease, multisystem sequelae, and prospects for treatment
A comprehensive review summarizing current knowledge on Long COVID mechanisms, multisystem sequelae, epidemiology, and potential treatment strategies, highlighting persistent viral antigens, immune and endothelial dysfunction, microbiome and mitochondrial contributions, and the …
DOI: 10.1080/25785826.2025.2570902